Deregulated FADD expression and phosphorylation in T-cell lymphoblastic lymphoma by Marín-Rubio, José L. et al.
Oncotarget61485www.impactjournals.com/oncotarget
www.impactjournals.com/oncotarget/ Oncotarget, Vol. 7, No. 38
Deregulated FADD expression and phosphorylation in T-cell 
lymphoblastic lymphoma
José L. Marín-Rubio1,2,3, María C. de Arriba4,5, María A. Cobos-Fernández1,2, 
Laura González-Sánchez1,2,6, Inmaculada Ors3, Isabel Sastre1, José Fernández-
Piqueras1,2,3,6, María Villa-Morales1,2,3,6 
1Centro de Biología Molecular Severo Ochoa (CBMSO), Consejo Superior de Investigaciones Científicas-Universidad Autónoma 
de Madrid (CSIC-UAM), Madrid, Spain
2IIS-Fundación Jiménez Díaz, Madrid, Spain
3Universidad Autónoma de Madrid, Departamento de Biología, Madrid, Spain
4Universidad Carlos III, Departamento de Bioingeniería, Madrid, Spain
5Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas (CIEMAT), Madrid, Spain
6Centro de Investigaciones Biomédicas en Red de Enfermedades Raras (CIBERER), Valencia, Spain
Correspondence to: María Villa-Morales, email: mvilla@cbm.csic.es 
José Fernández-Piqueras, email: jfpiqueras@cbm.csic.es
Keywords: T-cell lymphoblastic lymphoma, Fas-associated death domain protein (FADD), expression and phosphorylation, 
tumor aggressiveness, prognostic marker
Received: April 20, 2016    Accepted: August 11, 2016    Published: August 18, 2016
AbstrAct
In the present work, we show that T-cell lymphoblastic lymphoma cells exhibit 
a reduction of FADD availability in the cytoplasm, which may contribute to impaired 
apoptosis. In addition, we observe a reduction of FADD phosphorylation that inversely 
correlates with the proliferation capacity and tumor aggressiveness. The resultant 
balance between FADD-dependent apoptotic and non-apoptotic abilities may define the 
outcome of the tumor. Thus, we propose that FADD expression and phosphorylation 
can be reliable biomarkers with prognostic value for T-LBL stratification.
INtrODUctION
Precursor T-cell lymphoblastic neoplasms are 
aggressive hematological malignancies, derived from 
immature thymocytes in various differentiating stages. 
When they manifest as a mass lesion in the thymus/anterior 
mediastinum or in lymph nodes, with less than 25% marrow 
blasts, they are called T-cell lymphoblastic lymphoma 
(T-LBL) [1]. Molecular genetics of T-LBL are not well 
characterized, mainly due to the scarcity of samples [2]. 
Cancer cells frequently become resistant to a 
possible apoptotic insult mediated by FAS. Such resistance 
may be acquired by means of different mechanisms [3, 4]. 
In a recent study, we observed that 35% of human T-LBL 
cases exhibited reduced levels of Fas-associated death 
domain protein (FADD), suggesting that FADD reduction 
would be a frequent mechanism whereby FAS-mediated 
apoptotic signaling would be affected in this type of tumor 
[5]. FADD reduction has been also observed in tumor types 
like human non-small cell lung cancer [6], hepatocellular 
carcinoma [7] or thyroid adenoma/adenocarcinoma [8]. 
Although apoptosis is the canonical role for FADD, 
evidence compiled in the recent years indicate that FADD 
may also contribute to survival, cell cycle progression 
and cell proliferation, depending on its phosphorylation 
status and subcellular localization [9]. Such role for 
FADD in non-apoptotic functions is especially relevant 
in T cells at early stages of hematopoiesis [10, 11]. 
Moreover, thymopoiesis is partially defective in 
FADD-mutant mice [12]. FADD has been shown critical 
for regulating apoptosis of T-cell progenitors at the 
pre-TCR checkpoint, but also, it mediates signals 
required for efficient proliferation during transition from 
the CD4-CD8- double-negative (DN) to the CD4+CD8+ 
double-positive (DP) stage [13, 14]. Furthermore, FADD 
deficiency results in problems at multiple cell cycle 
checkpoints, not only inhibiting the entry of activated 
T cells into the cell cycle, but also blocking the cell 
cycle progression of already proliferating cells in G1 
phase [15, 16]. Altogether, this indicates that FADD may 
represent a tumor suppressor with positive and negative 
effects on T cell growth [14].
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FADD ability to promote the progression of T 
cells through the cell cycle seems to depend on its 
phosphorylation status [17, 18]. FADD phosphorylation 
occurs at Ser194 in humans and its murine equivalent 
Ser191 [19]. FADD phosphorylation might be biphasic in 
primary T cells, occurring during G0 to G1 followed by a 
dephosphorylation event during G1 to S and subsequent 
re-phosphorylation at G2/M [20]. Mice transgenic for the 
phosphomimetic mutation of FADD (Ser191Asp) showed 
analogous characteristics to FADD-deficient mice [9, 17]. 
Interestingly, the subcellular localization of FADD seems 
to be associated with this modification, specifically S194/
S191-P-FADD would be mainly nuclear [18]. However, 
the exact mechanism whereby nuclear FADD exerts its 
non-apoptotic function is not clear and the contribution 
of FADD subcellular localization to its function remains a 
recurrent issue. The simple hypothesis is that sequestration 
of FADD in the nucleus prevents its interaction with death 
receptors. But FADD could also bind other proteins to 
form a functional transcription factor complex to regulate 
gene transcription and activate survival mechanisms [9].
Several kinases have been proposed as responsible 
for FADD phosphorylation: HIPK3, which is induced by 
JNK, seems to promote FADD phosphorylation in prostate 
cells [21]. PKCζ has been described to phosphorylate 
FADD in certain cell types [22]. A model has been 
proposed [23], according to which CK1α and FADD 
colocalize on the mitotic spindle early in mitosis, resulting 
in phosphorylation of FADD at Ser194. It has been also 
reported the interaction between FADD and PLK1 [24, 
25], apparently in a G2/M-specific manner [26]. Finally, 
DUSP26 has been recently described as a phosphatase 
responsible for FADD dephosphorylation in breast cancer 
cells [27].
FADD phosphorylation has been analyzed in 
numerous solid tumors, however very limited and 
heterogeneous results are available in hematological 
cancers [28, 29]. Thus, whether alterations in FADD 
expression and phosphorylation are involved in T-cell 
lymphoblastic lymphoma kept an unresolved question.
Our study presents, for the first time, with a 
comprehensive study of FADD levels, phosphorylation 
status, regulators of FADD phosphorylation, FADD 
subcellular localization and function in T-cell 
lymphoblastic lymphoma. According to the results, FADD 
phosphorylation is altered in T-LBL, probably due to the 
combined action of several mechanisms: reduced FADD 
levels, reduced levels of HIPK3 and CK1α kinases and 
elevated levels of DUSP26 phosphatase. Altogether, 
FADD reduction may result in diminished apoptosis of 
tumor thymocytes. Moreover, two distinct sub-groups of 
T-LBL can be established based on S191-P-FADD levels, 
which correlate with different proliferation capacities 
and tumor aggressiveness. Thus, we propose that FADD 
expression and its phosphorylation can be reliable 
biomarkers with prognostic value for T-LBL stratification.
rEsULts
FADD and phospho-FADD levels are reduced in 
mouse t-LbL
We studied the levels of Fadd mRNA by 
quantitative RT-PCR in 9 healthy thymuses and 22 T-LBL 
samples from C57BL/6J mice. A significant reduction was 
observed in T-LBLs (fold-change = 20%, P < 0.0001), 
compared with the control group (Figure 1A). 
We discarded the presence of mutations in the 
Fadd promoter sequence of T-LBL samples (genomic 
coordinates chr7:144581400-144582801 from 
Ensembl Genome Browser), which might have affected 
transcription factors binding (data not shown). Also, 
an in-silico analysis of this region showed the most 
relevant transcription factors binding sites, as predicted 
by SABiosciences´ Text Mining Application and the 
UCSC Genome Browser (http://www.sabiosciences.com/
chipqpcrsearch.php?species_id=1&factor=Over+200+T
F&gene=FADD&nfactor=n&ninfo=n&ngene=n&B2=Se
arch). We counted on preliminary evidence from RNA-
sequencing data (unpublished), which indicated that one 
of those transcription factors, Ahr, exhibited a significant 
downregulation in all the T-LBL samples, in comparison 
with healthy thymuses. We validated these results by 
means of quantitative RT-PCR (Figure 1B). Interestingly, 
a regression analysis revealed a significant correlation 
between Fadd and Ahr mRNA levels in these samples.
At the protein level, total FADD and S191-P-
FADD were studied by Western blot in whole protein 
extracts of thymocytes from 13 healthy thymuses and 14 
T-LBL samples (Figure 1C, 1D). The statistical analysis 
after densitometry and β-actin normalization revealed a 
significant reduction of S191-P-FADD levels in T-LBLs 
(P = 0.019), expressed as the ratio [S191-P-FADD/FADD] 
(Figure 1D). This reduction was not due to the presence 
of mutations, as it was corroborated by Fadd cDNA 
sequencing (data not shown). We confirmed these results 
by immunohistochemistry (IHC) in tissue sections from 6 
healthy thymuses and 21 T-LBL samples (Figure 1E, 1F), 
which also revealed a significant reduction of the ratio 
[S191-P-FADD/FADD] in tumors (P < 0.001) (Figure 1F). 
Notably, a considerable inter-tumor heterogeneity 
regarding FADD and – particularly - S191-P-FADD levels 
was observed among the T-LBL samples. We performed a 
Kernel density plot, which showed a skewed distribution 
of the samples in two clusters with moderate and low 
levels of S191-P-FADD positivity by IHC, compared 
with the control group (Figure 1G). These clusters define 
two T-LBL sub-groups, which will be named Moderate 
and Low, with reference to their levels of S191-P-FADD. 
Interestingly, the comparison according to this sub-
classification revealed that the reduction of total FADD 
levels was statistically significant between the control 
group and the Low T-LBL sub-group (P = 0.012), but 
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not between the two T-LBL sub-groups (Figure 2B). The 
percentage of S191-P-FADD-positive cells, obtained from 
the IHC experiments, revealed significant differences in all 
the comparisons (P ≤ 0.01) and the ratio [S191-P-FADD/
FADD] resulted significantly diminished in the Low 
T-LBL sub-group, both compared with the control group 
(P < 0.001) and with the Moderate T-LBL sub-group 
(P < 0.001) (Figure 2A, 2B). 
FADD sub-cellular localization in mouse t-LbL
The sub-cellular localizations of FADD and S191-
P-FADD were also analyzed in control and T-LBL 
samples by IHC (Figure 2C–2E). Both the Moderate and 
Low T-LBL sub-groups exhibited a significant reduction 
of cytoplasmic FADD, compared with the controls (P ≤ 
0.001), but no significant difference existed between them 
(P = 1.000) (Figure 2D).
Besides, nuclear S191-P-FADD positivity showed 
no significant difference between the control group 
and the Moderate group (P = 1.000). However, the 
reduction in the Low group was statistically significant 
in both comparisons (P < 0.001) (Figure 2D). The ratio 
nuclear [S191-P-FADD/FADD] resulted significantly 
diminished both in the Moderate and Low T-LBL sub-
groups, in comparison with controls (P < 0.001), and also 
between them (P < 0.001) (Figure 2D). If we compared 
the relative distribution nucleus/cytoplasm between the 
groups, interesting conclusions emerged (Figure 2E). The 
distribution for total FADD in Moderate and Low T-LBLs 
Figure 1: FADD and P-FADD levels in t-LbL. (A, b) Fadd (A) and Ahr (B) mRNA levels were determined in healthy thymuses 
(CTRL) and T-cell lymphoblastic lymphoma samples (T-LBL) by quantitative RT-PCR. The results were normalized using the 2-∆∆CT 
method, referring Fadd or Ahr expression to those of G6pd and Hprt, and referenced to the control group. (c–F) Total FADD protein and 
S191-P-FADD levels were determined in CTRL and T-LBL groups by Western blot (C, D) and Immunohistochemistry (E, F). Representative 
images are shown for the WB (C) and IHC (E) experiments. WB images in (C) are cropped in favor of conciseness. The box-and-whisker 
plot analyses of the ratio [S191-P-FADD/FADD] for all the samples are shown for the WB (D) and IHC (F) experiments, indicating the 
statistical significance of the comparisons. (G) Kernel density plot showing T-LBLs density for S191-P-FADD levels (continuous line) and 
standard normal distribution of each cluster (dashed line). *P < 0.05. ***P ≤ 0.001.
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differed from that of the control group, with total FADD 
significantly decreasing in the cytoplasm of both T-LBL 
sub-groups (P = 0.002 and P = 0.025, respectively). 
Regarding S191-P-FADD, the relative distribution in the 
Moderate T-LBL sub-group was similar to that of the 
control group (P = 0.376), while the Low group presented 
with a significant reduction in the nucleus (P = 0.006). 
When expressed as the ratio [S191-P-FADD/FADD], 
we observed that the phosphorylated form of FADD was 
predominant in the nucleus of control thymocytes, while 
it became progressively redistributed in the thymocytes of 
the Moderate group (P = 1.000), but especially in the Low 
T-LBL group (P ≤ 0.001).
Apoptosis is reduced in t-LbL samples
The IHC analysis of active caspase-3 as a 
marker for apoptosis revealed a striking reduction in 
the percentage of positive cells in 38.1% (8/21) of the 
T-LBL samples analyzed, in comparison with controls 
(n = 9) (Figure 3A). The T-LBL samples shown to be 
negative for active caspase-3 belonged either to the so-
called Moderate or Low groups. This is consistent with 
the observation in Figure 2D that cytoplasmic FADD 
positivity was significantly reduced in both groups, 
compared with the controls, but no differences were 
found between them.
the "Moderate" and "Low" t-LbL sub-groups 
present different blast numbers and proliferation 
rates
The presence of blast cells and the proliferation 
rate were estimated by TdT and Ki67 immunostaining, 
respectively (Figure 3B, 3D and 3E). In healthy thymuses 
(n = 4), TdT was typically distributed asymmetrically, 
being the cortex highly positive and the medulla fully 
negative. Likewise, Ki67 was more abundant in the cortex, 
and principally localized in the outer part, adjoining 
the capsule around the thymus. This correlated with 
S191-P-FADD distribution, which presented with a 
majority of S191-P-FADD-staining in the outer cortex, 
whereas the positivity in medulla was weaker (Figure 3C). 
Interestingly, nearly all the positive cells in the outer cortex 
showed predominantly nuclear S191-P-FADD-staining.
As expected in T-LBL samples, there was no longer 
a clear demarcation of cortex and medulla (Figure 3B). 
Notwithstanding, the blast percentage (Figure 3D) and 
proliferation rate (Figure 3E) were significantly higher in 
the Moderate T-LBL sub-group, compared both with the 
control group (P = 0.024 and P = 0.002, respectively) and 
with the Low T-LBL sub-group (P = 0.038 and P ≤ 0.001), 
whereas no statistical difference was observed between the 
control group and the Low T-LBL sub-group (P = 1.000). 
Interestingly, a regression analysis revealed significant 
correlations between TdT (Figure 3D) or Ki67 (Figure 3E) 
and S191-P-FADD positivities, supporting the stratification 
of T-LBLs into Moderate and Low sub-groups. 
Our next step was to determine the levels of 
FADD and P-FADD that are able to exert apoptotic 
and non-apoptotic functions in the cell (Figure 3F–3H). 
We reconstituted FADD expression in the I 2.1 FADD-
deficient JURKAT cell line with 5 µg and 25 µg of 
FADD EX-V0108-Lv225 construct. Forty-eight hours 
after electroporation, the transfectants exhibited low 
and moderate P-FADD levels, respectively, compared 
with the parental FADD-wild type A3 JURKAT cell line. 
Upon apoptosis-induction with agonist anti-FAS antibody 
(CH11), only the parental FADD-wild type A3 JURKAT 
cell line showed an efficient execution of apoptosis, 
measured by PARP proteolysis (Figure 3F) and Annexin 
V/7-AAD staining (Figure 3G). None of the transfectants 
exhibited PARP proteolysis (Figure 3F); however, 
interesting differences were observed between them. The 
FADD-5 µg transfectant did not show any activation of 
the caspase cascade upon CH11-induction (Figure 3F), 
whereas the FADD-25 µg transfectant exhibited an 
apparent activation of Caspase-8 and a subtle but evident 
activation of Caspase-3 (Figure 3F). Furthermore, 23.7% 
of the cells in this condition exhibited early apoptosis 
measured as Annexin V+/7-AAD-, compared with 5.2% 
of cells in the FADD-5 µg condition (Figure 3G). 
Altogether, these results indicate that the increment 
in FADD levels leads to functional consequences, but 
suggest the presence of a threshold below which the cell 
is not able to execute generalized apoptosis.
On the other hand, the cell growth was determined 
at 72 hours (Figure 3H) and we found that the FADD-
5 µg transfectant did not show any difference in terms of 
proliferation, compared with its negative counterpart. On 
the contrary, the FADD-25 µg transfectant had proliferated 
significantly more. This indicates that the increment in 
FADD levels leads to functional consequences different 
from apoptosis.
the "Moderate" tumors are more aggressive 
than the "Low"tumors
A Kaplan-Meier survival curve analysis revealed 
that the median survival time was significantly longer 
for mice from the Low T-LBL sub-group, compared with 
that of the Moderate sub-group (22.7 vs. 21.0 weeks; 
Log-rank (Mantel-Cox) test, P = 0.0209) (Figure 4A). 
According to the Ann Arbor staging system, another 
measure of aggressiveness is the involvement of 
extralymphatic organs [30]. Very interestingly, the 
percentages of mice presenting hypertrophic spleen, 
nodes (either axillar, inguinal or mesenteric) and liver 
were significantly higher in the Moderate than in the Low 
sub-group (P < 0.001) (Figure 4B).
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Figure 2: Stratification of T-LBL and subcellular localization of FADD and P-FADD. (A, b) Total FADD protein and 
S191-P-FADD levels determined by IHC are shown for the so-called Moderate and Low T-LBL sub-groups, in comparison with the control 
group (CTRL). (A) Representative images are shown for each group. (B) The box-and-whisker plot analyses of total FADD, S191-P-FADD 
and the ratio [S191-P-FADD/FADD] for all the samples are shown, indicating the statistical significance of the comparisons. (c) To 
illustrate the subcellular localizations of FADD and S191-P-FADD, representative images acquired at 100 × magnification are shown. The 
black arrowheads illustrate cells with nuclear positivity, the black and white arrowheads illustrate cells with cytoplasmic positivity, and the 
open arrowheads illustrate negative cells. (D) The box-and-whisker plot analyses of cytoplasmic total FADD, nuclear S191-P-FADD and 
the nuclear ratio [S191-P-FADD/FADD] for all the samples are shown, indicating the statistical significance of the comparisons. (E) The 
relative distributions nucleus:cytoplasm of total FADD, S191-P-FADD and the ratio [S191-P-FADD/FADD] are represented for each group 
in bar charts, indicating the statistical significance of the comparisons.ns, not significant; *P < 0.05; **P < 0.01; ***P ≤ 0.001.
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Figure 3: Apoptosis, tumor and proliferation markers in t-LbL. (A) (D175)-cleaved-Caspase-3 levels are determined by IHC 
in healthy thymuses (CTRL) and T-LBL samples, as a measure for apoptosis. Representative images are shown for each group. (b, D, E) 
Terminal deoxynucleotidyl transferase (TdT) and Ki67 levels are determined by IHC in healthy thymuses (CTRL) and Moderate and Low 
T-LBL samples, as a measure for the T-LBL-characteristic blast presence and for proliferation, respectively. (B) Representative images are 
shown for each group. The box-and-whisker plot analyses of TdT (D) and Ki67 (E) percentages of positive cells for each group are shown, 
indicating the statistical significance of the comparisons. Also, their correlation with S191-P-FADD positivity are determined by regression 
analysis, indicating the coefficient of determination (R2) and the P value. (c) To illustrate the differential staining of S191-P-FADD in the 
cortex and medulla of healthy thymuses, representative images acquired at 100 × magnification are shown. (F, G) The apoptotic capacity 
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thymocyte developmental stages are differentially 
affected in "Moderate" and "Low" t-LbLs
The thymocyte populations content was determined 
by flow cytometry in the T-LBL samples, in comparison 
with healthy thymuses (Figure 4C). The T-LBL series 
exhibited a 1.7-fold-decrease in the CD4+CD8+ population 
(double-positive, DP) (mean ± SEM, 48.5% ± 7.02), in 
comparison with the control group (81.7% ± 0.63); this 
occurred in detriment of the other populations, with the 
highest increment in the CD4-CD8− (double-negative, DN) 
subset, with a 4.5-fold-increase in tumors (3.5% ± 0.17 in 
controls vs. 15.8% ± 4.96 in T-LBLs).
Interestingly, the most prominent decrease of the 
DP population observed in the T-LBL series occurred to 
the same extent in both the Moderate (48.8% ± 9.09) and 
Low (47.9 ± 11.98) sub-groups. The concomitant increase 
in the DN population exhibited, however, a different 
behavior in the two sub-groups, with a level similar 
to that of the healthy thymuses in the Low sub-group 
(5.8% ± 2.40), but higher in the Moderate sub-group 
(21.2% ± 7.13) (6.1-fold-increase).
FADD phosphorylation regulators in mouse 
t-LbL
Several putative regulators of FADD 
phosphorylation have been proposed: the kinases HIPK3, 
PKCζ, CK1α, PLK1, and the phosphatase DUSP26. We 
analyzed all of them by Western blot in control and T-LBL 
samples from the same series used for the analysis of 
FADD and S191-P-FADD, by means of specific detection 
of PKCζ, T410-P-PKCζ, T560-P-PKCζ, PLK1, T210-P-
PLK1, HIPK3, CK1α and DUSP26 (Figure 5).
The statistical analysis after densitometry and β-actin 
normalization revealed no significant alteration for PKCζ 
levels or its phosphorylated (active) forms in the controls 
versus T-LBLs comparison, as shown by the ratios [T410-
P-PKCζ/PKCζ] and [T560-P-PKCζ/PKCζ] (P = 1.000 and 
P = 0.111, respectively) (Figure 5A, 5B). Likewise, the 
ratio [T210-P-PLK1/PLK1] did not change significantly 
between controls and T-LBLs (P = 0.325) (Figure 5C, 5D). 
Using molecules reported to inhibit PKCζ (Gö6976) [31] 
and PLK1 (GW842682X) [32] kinase activities, we did 
not observe any effect on FADD phosphorylation either in 
human (JURKAT) or murine (BW5147.3) T-LBL/ALL cell 
lines (Supplementary Figure S1).
We found significant reductions of HIPK3 and 
CK1α expression levels in T-LBL samples (P < 0.001 
and P = 0.012, respectively), together with a significant 
increase of DUSP26 (P ≤ 0.001) (Figure 5E–5J). Then 
we sought to corroborate the role of these elements as 
bona fide regulators, especially as their activation levels 
could not be evaluated by specific detection of active 
forms. No specific inhibitors are available for HIPK3, 
but specific inhibition of JNK activity using SP600125 
leads to a concomitant decrease in HIPK3 expression 
and FADD phosphorylation [21]. Using this inhibitor, we 
found a dose-dependent reduction of S194/S191-P-FADD 
in JURKAT and BW5147.3 cell lines (Figure 6A, 6B). 
Likewise, a dose-dependent reduction of S194/S191-
P-FADD was observed in JURKAT and BW5147.3 cell 
lines after pharmacological inhibition of CK1α with a 
molecule reported to suppress its kinase activity, CKI-7 
[26] (Figure 6C, 6D). Finally, we observed an increase 
of FADD phosphorylation after inhibition of DUSP26 
phosphatase with the molecule NSC-87877, known to 
suppress its enzymatic activity [27] (Figure 6E, 6F).
 DIscUssION
Changes in FADD expression and post-translational 
modification in cancer might be cell type-specific, thus 
resulting either in loss of apoptosis or gain of non-
apoptotic functions [33, 34]. This would explain apparent 
discrepancies between studies. For example, FADD 
overexpression and increased phosphorylation correlate 
with poor clinical outcome and reduced patient survival in 
human lung adenocarcinoma [34]. More recently, FADD 
expression and phosphorylation were reported to be 
pro-tumorigenic in oncogenic KRAS-driven cancers [26]. 
However, mutations of the Ras family are relatively rare 
in T-cell acute lymphoblastic leukemia [35]. Collected 
evidence from COSMIC database corroborate that mutations 
in KRAS are not frequent in hematological malignancies, 
with a general incidence of 4.92%, which is even lower in 
T-ALL/LBL (1.52%) (http://cancer.sanger.ac.uk/cosmic).
On the other hand, FADD reduction has been 
reported in different tumor types [6–8]. A study on acute 
myeloid leukaemia [36] reported that reduced FADD in 
was evaluated by WB in a FADD-reconstitution assay of I 2.1 FADD-deficient JURKAT cell line (JURKAT-FADD-KO). As a positive 
control, the parental FADD-wild type A3 JURKAT cell line is used (JURKAT-wt). As a negative control, I 2.1 cells were electroporated 
(EP) with the negative vector EX-NEG-Lv225. I 2.1 cells were electroporated with 5 or 25 µg of EX-V0108-Lv225 vector (FADD-5 µg 
and FADD-25 µg, respectively). Each condition was either left untreated (−) or treated for 24 h with irrelevant IgM isotype control 
antibody (IgM) or with agonist anti-FAS antibody (CH11). An aliquot was used for protein extraction and specific immunodetection of 
Caspases-8 and 3 activation and PARP proteolysis (F) and another was analyzed for Annexin V / 7-AAD staining by flow cytometry (G). 
WB images in (F) are cropped in favor of conciseness. (H) The proliferative capacity was evaluated in the same FADD-reconstitution 
assay. The normalized proliferation rates of the FADD-5 µg and FADD-25 µg conditions (FADD), and their corresponding EX-NEG-Lv225 
electroporations (NEG), are represented in a bar chart, expressed as the ratio [number of cells at 72 h post-EP / number of cells at 72 h post-
EP with the corresponding EX-NEG-Lv225 condition]. ns, not significant; *P < 0.05; **P < 0.01; ***P ≤ 0.001.
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leukaemic cells at diagnosis indicated bad prognosis. It 
has been postulated that, in those many studies in which 
tumor progression has been shown to correlate with 
reduced FADD or phospho-FADD, the apoptotic role of 
FADD is stressed, and thus is FADD regarded as a tumor 
suppressor gene [9, 36].
We report here that FADD is significantly reduced 
in murine T-LBL samples. We discarded the upregulation 
of several microRNAs targeting Fadd as a mechanism 
underlying FADD decrease in T-LBL (data not shown). 
However, we find a very significant reduction of the 
putative transcription factor Ahr, which prompts us to 
Figure 4: Aggressivenes of the “Moderate” and “Low” t-LbL sub-groups. (A) Kaplan-Meier survival curve analysis 
comparing mice from the Moderate and Low T-LBL sub-groups. (b) Involvement of secondary organs in mice from the Moderate and Low 
T-LBL sub-groups, expressed in a bar chart as the percentage of cases with organ affectation. The statistical significance of the comparisons 
is indicated. (c) Thymocyte populations content, in percentage, in healthy thymuses (CTRL), the whole T-LBL series (T-LBL), and the 
Moderate and Low sub-groups. DN, CD4−CD8− (double-negative). DP, CD4+CD8+ (double-positive). SP4, CD4+CD8− (single-positive CD4). 
SP8, CD4−CD8+ (single-positive CD8). ***P ≤ 0.001.
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suggest that significant downregulation of Ahr in T-LBLs 
may be involved in FADD reduction in these samples.
However, the ability of FADD as a “proliferation-
apoptosis coupler” [20] introduces an additional level of 
complexity. Not only FADD reduction may contribute to 
cancer, but also its phosphorylation status would determine 
its proliferative role. Additionally, FADD has a critical role 
in thymopoiesis, which potentially makes T-LBL a type of 
cancer particularly susceptible to FADD alterations. 
FADD phosphorylation has been analyzed in 
numerous solid tumors, for example in prostate cancer 
cells, where a reduction of FADD phosphorylation has 
been reported [37, 38]. These and other authors suggest 
that assessment of FADD phosphorylation may be useful 
as a prognostic biomarker, and that induction of FADD 
phosphorylation could be a target in cancer therapy 
[39]. However, very limited results regarding FADD 
phosphorylation are available in hematological human 
cancers [29]. We report here that murine T-LBL samples 
exhibit a pronounced reduction of S191-phospho-FADD, 
thus resulting the ratio [S191-P-FADD/FADD] 
considerably diminished. However, a considerable inter-
tumor heterogeneity was observed. A similar scenario has 
been previously reported in T-cell tumors and B-cell non-
Hodgkin lymphoma, where both phospho-FADD positivity 
and signal intensity exhibited a high variation [28, 29]. 
We establish two T-LBL sub-groups (Moderate and 
Low), according to S191-P-FADD positivity determined 
by IHC. Parameters of tumor aggressiveness like survival 
time and secondary organ involvement support our 
stratification in Moderate and Low T-LBL sub-groups.
Cytoplasmic FADD positivity exhibits a significant 
reduction in T-LBL cells from both groups, consistent 
with a reduced participation of FADD in apoptosis. 
On the other hand, S191-P-FADD positivity exhibits a 
reduction particularly striking in the nucleus of thymocytes 
Figure 5: FADD phosphorylation regulators in t-LbL. (A, b) PKCζ, T410-P-PKCζ, T560-P-PKCζ, PLK1, T210-P-PLK1, 
HIPK3, CK1α and DUSP26 levels were determined in healthy thymuses (CTRL) and T-cell lymphoblastic lymphoma samples (T-LBL) 
by Western blot. (A, c, E, G, I) Representative images are shown. WB images are cropped in favor of conciseness. (B, D, F, H, J) The 
box-and-whisker plot analyses of the ratios [T410-P-PKCζ/PKCζ], [T560-P-PKCζ/PKCζ], [T210-P-PLK1/PLK1], and the levels of HIPK3, 
CK1α and DUSP26 for all the samples are shown, indicating the statistical significance of the comparisons. *P < 0.05. ***P ≤ 0.001.
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belonging to the Low T-LBL group. Since the proliferation 
rate of this group is significantly lower than that of the 
Moderate T-LBL group, this is consistent with a role for 
FADD in functions other than apoptosis, like proliferation. 
This is in agreement with previous observations associating 
Ki67 and phospho-FADD in human lung adenocarcinoma 
[34] and B-cell non-Hodgkin lymphoma [28]. 
Since early T cell development in FADD-deficient 
mice is inhibited at the DN to DP transition [13], we 
suggest that DP reduction in murine T-LBLs might be 
explained, at least in part, based on FADD decrease. 
On the other hand, the differential accumulation of DN 
cells in tumors from the Moderate and Low sub-groups 
suggests that FADD might intervene in the differentiation 
and proliferation of tumor thymocytes, but these processes 
would be uncoupled. 
Regarding FADD phosphorylation, various 
regulators may operate. Classical cell cycle-regulating 
kinases such as cdc and CDKs, as well as PKCs, have been 
discarded [40]. More specifically, it has been reported that 
PKCζ does not phosphorylate FADD in DU145 prostate 
cancer cells [21]. This is in agreement with our results 
in T-LBL, where no alterations in PKCζ activation were 
observed, nor any effect on FADD phosphorylation upon 
Figure 6: Inhibition assays for FADD phosphorylation regulators. (A, b) Decrease of FADD phosphorylation in JURKAT (A) 
and BW5147.3 (B) cell lines, upon inhibition of HIPK3 by SP6000125-treatment for 5 h and 2 h, respectively, and the indicated doses. 
Inhibition was validated based on decrease in S63-P-c-jun and HIPK3 levels. (c, D) Decrease in FADD phosphorylation in JURKAT (C) 
and BW5147.3 (D) cell lines, upon inhibition of CK1α by CKI-7-treatment for 12 h and 8 h, respectively, and the indicated doses. Inhibition 
was validated based on decrease in S45-P-β-catenin level. (E, F) Increase of FADD phosphorylation in JURKAT (E) and BW5147.3 (F) 
cell lines, upon inhibition of DUSP26 by NSC-87877-treatment for 3 h, followed by 30 min-incubation of cells with 1 mM H2O2, and the 
indicated doses. Inhibition was validated based on increase of T180/Y182-P-p38 levels in JURKAT, but this effect could not be observed 
in BW5147.3. All WB images are cropped in favor of conciseness.
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pharmacological inhibition in T-LBL/ALL cell lines. We 
obtained similar results for PLK1. We found, however, that 
HIPK3 and CK1α kinases exhibit a significant reduction 
in T-LBLs, together with a significant increase of the 
phosphatase DUSP26. We suggest that these enzymes 
might co-operate in regulating FADD phosphorylation in 
thymocytes, and that their concomitant deregulation might 
underlie the alterations we observe in T-LBLs.
We propose a model of double-threshold (Figure 7), 
where the level of cytoplasmic FADD would define its 
canonical function as an apoptotic adapter and the level 
of nuclear S191-P-FADD would define its participation in 
proliferative, cell cycle control or survival non-canonical 
processes. According to this model, tumor cells within the 
window between the two thresholds (Moderate T-LBLs) 
would lack proper FADD-involved apoptosis, but would 
be competent for FADD-mediated proliferation, cell cycle 
and/or survival, thus becoming more aggressive. Control 
cells would be balanced in terms of FADD-mediated 
apoptosis and proliferation, with FADD levels enabling 
them for both functions, whereas tumor cells from the 
Low sub-group would be incompetent both for FADD-
mediated apoptosis and proliferation, thus resulting in less 
aggressive tumors.
In summary, our data indicate that T-LBL 
cells exhibit a reduction of FADD availability in the 
cytoplasm, which may contribute to impaired apoptosis. 
But also, our results indicate that different statuses of 
FADD phosphorylation may be a key element providing 
the basis for tumor stratification. The resultant balance 
between FADD-dependent apoptotic and proliferative 
capacities may define the outcome of the tumor. With 
this study, we gain knowledge on the status, regulation 
and functionality of FADD in T-LBL, which will help 
establish a better prognosis and contribute to develop 
new therapeutic strategies. 
Figure 7: Model for differential aggressiveness of the t-LbL sub-groups. Two different thresholds for cytoplasmic FADD level 
(left axis, in blue) and nuclear S191-P-FADD level (right axis, in green) in T-LBL samples define the limits for apoptosis and proliferation 
competency, respectively. T-LBL samples with cytoplasmic FADD levels below the blue threshold are not able to undergo FADD-dependent 
apoptosis, which may characterize them as tumors. However, the green threshold for nuclear S191-P-FADD level determines the capacity 
of the tumor cells to undergo FADD-dependent proliferation, provided that FADD gets phosphorylated and properly distributed to the 
nucleus. Thus, those samples between the two thresholds, the Moderate T-LBL sub-group, would present with a more aggressive phenotype 
than those below both of them, the Low T-LBL sub-group. Accordingly, a healthy thymus would be balanced in terms of FADD-mediated 




The experiments with primary tumors were 
performed using a mouse model of T-LBL. We adhered 
to the ethical considerations dictated by the European 
Directive 2010/63/EU and Real Decreto 53/2013 on 
the protection of animals used in scientific procedures. 
4-week-aged C57BL/6J female mice obtained from 
The Jackson Laboratory (The Jackson Laboratory, 
Bar Harbor, ME, USA) were either left untreated 
(healthy thymuses, control group) or subjected to T-cell 
lymphoblastic lymphoma (T-LBL group) induction as 
described in [41]. A portion of the thymuses (control or 
T-LBL) was mechanically dispersed and strained through 
a nylon mesh (BD Biosciences, San Jose, CA, USA) to 
isolate the thymocytes. Another portion was fixed for 
Immunohistochemistry.
cell culture
JURKAT cell lines A3 (ATCC® CRL-2570™) and 
I 2.1 (ATCC® CRL-2572™), and BW5147.3 (Thy-1-e) 
cell line (ATCC® TIB-234™) were purchased from the 
American Type Culture Collection (ATCC, Manassas, VA, 
USA). ATCC routinely performs cell lines authentication, 
using STR analysis (DNA profiling) as a procedure. Cell 
experimentation was always performed within a period 
not exceeding 6 months after resuscitation. Cells were 
cultured in RPMI 1640 (Gibco, Grand Island, NY, USA) 
supplemented with 10% or 15% FBS (PAA Laboratories, 
GE Healthcare Life Sciences, Velizy-Villacoublay, France), 
2 mM L-Glutamine (Merck Millipore, Billerica, MA, USA) 
and 1 mM sodium pyruvate (Merck Millipore). Cultures 
were maintained at 37°C in 5% CO2 humidified atmosphere.
Gene expression analysis
Total RNA from murine samples was obtained using 
TriPure Reagent (Roche Applied Science, Indianapolis, 
IN, USA), following manufacturer’s instructions. 
Fadd and Ahr gene expressions were determined at the 
transcriptional level by real-time quantitative RT-PCR 
from total RNA in two steps, using first the High-Capacity 
RNA-to-cDNA™ Kit (Applied Biosystems, Foster City, 
CA, USA), then the FastStart Universal SYBR Green 
Master (Rox) (Roche, Mannheim, Germany). Expression 
values of G6pd and Hprt in the same samples were used 
for normalization, using the 2-∆∆CT method [42]. Primers 
are indicated in Supplementary Table S1.
Fadd cDNA and fadd promoter amplification 
and sequencing
One microgram of RNA from T-LBL samples was 
reverse-transcribed using SuperScript® VILO™ cDNA 
Synthesis Kit (Invitrogen, Carlsbad, CA, USA), and Fadd 
cDNA was amplified by PCR using Expand High Fidelity 
PCR System (Roche Applied Science) at T(annealing) = 
55ºC, with the primers indicated in Supplementary 
Table S1.
Genomic DNA from T-LBL samples was obtained 
using TriPure Reagent (Roche Applied Science), following 
manufacturer’s instructions.  Fadd promoter was amplified by 
PCR using GC-Rich PCR System (Roche Applied Science) 
at T(annealing) = 59.8ºC and 0 M Resolution Solution, with 
the primers indicated in Supplementary Table S1.
The PCR products were purified using Wizard SV 
Gel and PCR Clean-up System (Promega Corporation, 
Madison, WI, USA). Sequencing reactions were performed 
using either an ABI Prism 310 Automated Sequencer or 
an 3730XL ABI Sequencer, from Applied Biosystems 
(Applied Biosystems, Thermo Fisher, Waltham, MA, USA), 
and the primers indicated in Supplementary Table S1. 
For comparisons, the program L-Align from ExPASy 
Molecular Biology Server was used.
Antibodies and reagents
Primary and secondary antibodies used for 
immunodetection are summarized in Supplementary 
Table S2. Gö6976, SP600125 and NSC-87877 were 
purchased from Calbiochem (Merck Millipore), CKI-7 from 
Sigma-Aldrich (Sigma-Aldrich, St. Louis, MO, USA) and 
GW843682X from Tocris Bioscience (Tocris Bioscience, 
Bristol, United Kingdom).
Western blot
Total proteins from murine samples were obtained 
using TriPure Reagent (Roche Applied Science), following 
manufacturer’s instructions. Total proteins from cell 
lines were obtained using radioimmunoprecipitation 
assay (RIPA) cell lysis buffer. Protein extracts were 
supplemented with 2 mM phenylmethylsulphonyl fluoride 
(PMSF), 2.5 µl/ml Protease Inhibitor Cocktail and 10 µl/ml 
Phosphatase Inhibitor Cocktail 2 (Roche Diagnostics 
GmbH, Mannheim, Germany). Ten micrograms-
aliquots were electrophoresed in 12% SDS-PAGE with 
β-mercaptoethanol, then electrotransferred to Immobilon-P 
transfer membranes (Merck Millipore).
The peroxidase activity was developed using 
WesternBright ECL Detection System (Advansta, Menlo 
Park, CA, USA). ImageQuant LAS 4000 digital imaging 
system (GE Healthcare Bio-Sciences, Piscataway, NJ, 
USA) was used for acquisition of images, and Scion 
Image Software (Scion Corporation, NIH, Frederick, MD, 
USA) for band densitometry.
Immunohistochemistry
Formalin-fixed and embedded paraffin tissues were 
deparaffinised and rehydrated using standard protocols 
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and subjected to heat-induced antigen retrieval in Tris-
EDTA buffer (pH = 9.0).  
Frozen tissues were obtained after 10% formalin-
fixation for 2 h, cryoprotection with 30% sucrose in 
phosphate buffer saline (PBS) for 24 h, and embedding in 
Tissue-Tek® O.C.T ™ Compound (Sakura Finetek Europe 
B.V., Alphen aan den Rijn, The Netherlands). 10 µm-
sections were used.
Endogenous peroxidase activity was reduced by 3% 
H2O2-pre-treatment for 30 min. Dako REAL
™ antibody 
diluent (Dako, Glostrup, Denmark) was the blocking 
buffer. We used liquid DAB+ substrate chromogen system 
(Dako) for visualization. The sections were counterstained 
with Mayer’s hematoxylin (Sigma-Aldrich). An Axiovert 
200 inverted microscope (Carl Zeiss, Oberkochen, 
Germany) and a SPOT RT Digital Scanning Camera 
(Diagnostic Instruments, Sterling Heights, MI, USA) 
at 63 × magnification were used for image analysis. 
Photographic material was acquired with an Olympus 
BX61 microscope (Olympus America, Melville, NY, USA) 
at 20 × and 100 × magnification. Two authors evaluated 
immunostaining independently. Irrespective of intensity, 
the percentages of positive cells versus total cell number 
were calculated using ten random representative fields per 
section. Fiji-Image J free software (http://fiji.sc; National 
Institutes of Health, Bethesda, MD, USA) was used for 
analysis, applying the  Image/Colour deconvolution, 
Image/Adjust/Threshold and Analyze/Analyze Particles 
tools as published previously [43]. 
In vitro FADD reconstitution
I  2.1 FADD-deficient JURKAT cells were 
electroporated with EX-V0108-Lv225 or EX-NEG-
Lv225 constructs (GeneCopoeia, Rockville, MD, USA) 
using a Gene Pulser MXcell Electroporation System 
(Bio-Rad Laboratories, Hercules, CA, USA). 107 cells 
in 500 μl of complete medium were subjected to 280V, 
950 μF, with 5 μg or 25 μg of vector. Electroporated 
cells were harvested in 10 ml of complete medium and 
analyzed for protein expression 48 h post transfection, 
both by flow cytometry - testing GFP positivity with a 
FACS Canto II (Becton-Dickinson, Franklin Lakes, NJ, 
USA) for percentage and mean fluorescence intensity - 
and Western blot. Then, 2 × 105 cells at 106 cells/ml were 
treated for 24 h with agonist anti-FAS mouse monoclonal 
antibody (clone CH11; Merck Millipore) or mouse IgM λ 
isotype control (clone 11E10; Beckman Coulter, Nyon, 
Switzerland), and aliquoted for (1) protein extraction 
and WB and for (2) Annexin V/7-AAD apoptosis assay 
by flow cytometry using PE Annexin V Apoptosis 
Detection Kit I (BD-Pharmingen™) and a FACSCalibur 
flow cytometer (Becton-Dickinson). In parallel, untreated 
transfected cells were followed for cell growth, based on 
Trypan blue exclusion viability test.
Flow cytometry analysis
Freshly isolated thymocytes from healthy thymuses 
and T-LBL samples were examined by flow cytometry. 
A CD3/TdT/CD4/CD8 4-colour analysis was performed 
on a FACSCalibur flow cytometer (BD Biosciences). 
25 000 cells were analyzed and background levels were 
determined with isotype-matched control antibodies 
(Supplementary Table S2).
Data analyses were performed using FlowJo 
(Flowjo, LLC, OR, USA).
statistical analyses
Significances were determined by a Mann-Whitney 
U test and a Bonferroni correction using the Statistical 
Package for the Social Sciences software (SPSS v.23.0, 
IBM Corporation, Somers, NY, USA). Fisher’s exact test 
was used to compare the distribution of two categories. 
Statistical analysis of Kaplan-Meier survival curves was 
performed by the Mantel-Cox method, using GraphPad 
Prism 6 (GraphPad Software, La Jolla, CA, USA). 
Kernel density plot was performed with R free software 
(R Development Core Team, version 3.2.3).
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